ARTELO BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ARTELO BIOSCIENCES, INC. (ARTL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 4.00 thousand shares for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2023-03-31
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was -56.00K shares, a 180.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-06-30 was 60.00K shares, a 90.08% decline year-over-year.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-11-30 was 0.00 shares, a 100.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 2.76M shares, a 96.28% decline from fiscal 2020.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 74.00M shares, a 59.78% decline from fiscal 2019.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 184.00M shares, a 367900.00% increase from fiscal 2018.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 50.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 4 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|---|
| 2022-09-30 | -56.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 4.00K shares derived: sum of 2 quarters · filed 2022-11-08 | 4.00K shares 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | 60.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 60.00K shares 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-12 | |||||
| 2021-12-31 | 2.15B shares 10-KT · filed 2022-03-21 | |||||
| 2021-11-30 | 0.00 shares 10-Q · filed 2022-01-12 | 70.00K shares derived: sum of 2 quarters · filed 2022-03-21 | 675.10K shares derived: sum of 3 quarters · filed 2022-03-21 | 2.64M shares derived: sum of 4 quarters · filed 2022-03-21 | ||
| 2021-08-31 | 70.00K shares derived: 10-KT 12 month − 10-Q 9 month · filed 2022-03-21 | 675.10K shares derived: sum of 2 quarters · filed 2022-03-21 | 2.64M shares derived: sum of 3 quarters · filed 2022-03-21 | 2.76M shares 10-KT · filed 2022-03-21 | 2.76B shares 10-K · filed 2021-11-29 | |
| 2021-05-31 | 605.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-07-12 | 2.57M shares derived: sum of 2 quarters · filed 2021-07-12 | 2.69M shares 10-Q · filed 2021-07-12 | 76.61M shares derived: sum of 4 quarters · filed 2023-03-31 | ||
| 2021-02-28 | 1.96M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-04-13 | 2.08M shares 10-Q · filed 2021-04-13 | 76.01M shares derived: sum of 3 quarters · filed 2023-03-31 | 76.01M shares derived: sum of 4 quarters · filed 2023-03-31 | ||
| 2020-11-30 | 120.00K shares 10-Q · filed 2021-01-14 | 74.05M shares derived: sum of 2 quarters · filed 2023-03-31 | 74.05M shares derived: sum of 3 quarters · filed 2023-03-31 | 74.12M shares derived: sum of 4 quarters · filed 2023-03-31 | ||
| 2020-08-31 | 73.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 73.93M shares derived: sum of 2 quarters · filed 2023-03-31 | 74.00M shares derived: sum of 3 quarters · filed 2023-03-31 | 74.00M shares 10-K · filed 2023-03-31 | 74.00K shares 10-K · filed 2020-11-04 | |
| 2020-05-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-07-13 | 74.00K shares derived: sum of 2 quarters · filed 2020-07-13 | 74.00K shares 10-Q · filed 2020-07-13 | 184.07M shares derived: sum of 4 quarters · filed 2021-11-29 | ||
| 2020-02-29 | 74.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-04-13 | 74.00K shares 10-Q · filed 2020-04-13 | 184.07M shares derived: sum of 3 quarters · filed 2021-11-29 | 184.07M shares derived: sum of 4 quarters · filed 2021-11-29 | ||
| 2019-11-30 | 0.00 shares 10-Q · filed 2020-01-14 | 184.00M shares derived: sum of 2 quarters · filed 2021-11-29 | 184.00M shares derived: sum of 3 quarters · filed 2021-11-29 | |||
| 2019-08-31 | 184.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-29 | 184.00M shares derived: sum of 2 quarters · filed 2021-11-29 | 184.00M shares 10-K · filed 2021-11-29 | 184.00K shares 10-K · filed 2019-11-25 | ||
| 2019-05-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-07-15 | 0.00 shares 10-Q · filed 2019-07-15 | ||||
| 2019-02-28 | 0.00 shares 10-Q · filed 2019-04-15 | |||||
| 2018-08-31 | 50.00K shares 10-K/A · filed 2019-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |